Thyroidectomy with out Radioiodine in Individuals with Low-Hazard Thyroid Most cancers

From the Division of Nuclear Drugs and Endocrine Oncology (S.L., L. Lamartina, M.-J.S.), the Department of Medical Biology and Pathology (A.A.G., L. Lacroix), and the Biostatistics and Epidemiology Workplace, Oncostat, INSERM Unité 1018 (I.B.), Gustave Roussy and Université Paris-Saclay, Villejuif, the Nuclear Drugs Office, Hospices Civils de Lyon, Groupement Hospitalier Est, Bron (C.B.), the Endocrine Oncology Division, Support Publique–Hôpitaux de Paris (AP–HP) Hôpital Saint-Louis (C.N.C.), and the Thyroid and Endocrine Tumors Unit, Pitié–Salpétrière Hospital AP–HP, Institute of Most cancers IUC Sorbonne University (L. Leenhardt), Paris, the Division of Professional medical Imaging, Nuclear Medicine, IUCT Oncopole Toulouse–Institut Claudius Regaud (S.Z.), and the Nuclear Medicine Section, CHU Rangueil (D. Bastie), Toulouse, the Office of Endocrinology–Metabolic Ailments, Hôpital Saint-André, Centre Hospitalier Universitaire (CHU) de Bordeaux (B.C.), and the Thyroid Oncology and Nuclear Medication Division, Institut Bergonié (Y.G.), Bordeaux, the Endocrine Section, CHRU de Lille–Hôpital Claude Huriez, Lille (C.D.C.), the Nuclear Drugs Section, Centre Jean Perrin, Clermont-Ferrand (A.K.), the Nuclear Medicine Department, Centre Eugene Marquis, Rennes (M.-L.B.), the Nuclear Medicine Office, Centre Georges François Leclerc, Dijon (I.D.), the Nuclear Medicine Section, Centre Henri Becquerel and Laboratoire QUANTif, Rouen (P.V.), the Nuclear Medicine Section, Centre René Gauducheau, Saint Herblain (D.R.), the Nuclear Medication Section, Centre Paul Strauss, Strasbourg (O.S.), the Nuclear Medicine Division, Antoine Lacassagne, Nice (D. Benisvy), the Endocrine Section, Centre Hospitalier Régional Universitaire (CHRU) de Nancy, Hôpitaux de Brabois, Vandoeuvre Les Nancy (M.K.), the Nuclear Medicine Division, CHU Grenoble–Alpes, Grenoble (J.R.), the Nuclear Medicine Section, Institut du Most cancers de Montpellier, Institut Régional du Most cancers Val d’Aurelle, Montpellier (M.-C.E.), the Nuclear Medication Department, Institut Curie Web page Saint-Cloud, Saint-Cloud (C.N.), the Nuclear Drugs Section, Centre Léon Bérard, Lyon (A.-L.G.), the Endocrine Office, CHU Saint Pierre, Saint Pierre (N.L.M.), the Nuclear Drugs Section and Thyroid Device, Centre François Baclesse, Caen (S.B.), the Endocrine Division, Institut du Thorax, CHU de Nantes–Hopital Laennec Saint-Herblain, Nantes (D.D.), the Endocrine Section, CHU La Cavale Blanche, Brest (N.R.), the Nuclear Medication Department, Institut de Cancérologie de l’Ouest, Angers (O.M.), the Endocrine Division, CHU Dupuytren, Limoges (A.D.), the Thyroid Unit, Institut Jean Godinot, Reims (C.S.), and the Endocrine Department, CHU de Guadeloupe, Hôpital Ricou, Les Abymes (F.-L.V.) — all in France.

Dr. Leboulleux can be contacted at [email protected] or at the Department of Nuclear Medicine and Endocrine Oncology, Gustave Roussy, Université Paris Saclay, 114 Rue Edouard Vaillant, 94805 Villejuif, France.